Key Takeaway: Oruka Therapeutics, Inc. (Nasdaq: ORKA) announced its participation in Piper Sandler’s 36th Annual Healthcare Conference, scheduled for December 3rd, 2024. The company is focused on developing novel biologics aimed at treating chronic skin diseases, including plaque psoriasis. Oruka's mission emphasizes achieving high rates of disease clearance with minimal dosing frequency, reflecting its commitment to improving patient outcomes.
Price reaction · baseline $21.13 (2024-11-18 close) · hit after-hours · clean, no other ORKA news in the window
day 0 close · peak
+5.5%
day 1
+5.1%
day 3
-1.8%
Market Sentiment Analysis
POSITIVE FACTORS
Oruka Therapeutics is advancing innovative biologics for chronic skin diseases.
The company aims for infrequent dosing, enhancing patient convenience.
Oruka's approach highlights a commitment to significant disease clearance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+307%
120-day peak, hindsight
Typical move
13%
average across 4 past catalysts
Cash runway
~102 mo
Minimal dilution risk
Lead asset
ORKA-001
Phase 2 · Plaque Psoriasis
Full Press Release Details
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler’s 36th Annual Healthcare Conference:
Date: Tuesday, December 3rd, 2024
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Frequently Asked Questions
What is Oruka Therapeutics focused on?
Oruka Therapeutics is focused on developing novel biologics for chronic skin diseases.
What chronic skin condition does Oruka aim to treat?
Oruka specifically targets plaque psoriasis among other chronic skin conditions.
How often can patients expect to dose Oruka's treatments?
Patients may dose Oruka's treatments as infrequently as once or twice a year.
Where can I find more information about Oruka Therapeutics?
More information is available on Oruka's website at www.orukatx.com.
When is Oruka's participation at the Piper Sandler Conference?
Oruka will participate in the conference on December 3rd, 2024.